Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV
By Rediff Money Desk, New Delhi Aug 01, 2024 13:34
Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus (RSV) in infants and children up to 24 months.
![Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV](https://im.rediff.com/money/2017/dec/05sanofi.jpg)
New Delhi, Aug 1 (PTI) Sanofi India on Thursday said it has received marketing authorisation approval from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus in India.
Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.
It is also administered to children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants.
"Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India," Sanofi Vaccines (India) General Manager Preeti Futnani stated.
In March 2017, Sanofi and AstraZeneca announced an agreement to develop and commercialise Beyfortus.
Under the terms of the agreement, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities and records revenues.
Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.
It is also administered to children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants.
"Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India," Sanofi Vaccines (India) General Manager Preeti Futnani stated.
In March 2017, Sanofi and AstraZeneca announced an agreement to develop and commercialise Beyfortus.
Under the terms of the agreement, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities and records revenues.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.76 ( -4.83)
- 96015373
- Srestha Finvest
- 2.16 ( -1.82)
- 42635134
- Vodafone Idea L
- 15.99 ( -1.72)
- 34025982
- Reliance Power L
- 32.93 (+ 0.21)
- 22757589
- YES Bank Ltd.
- 26.27 ( -0.87)
- 17617211
MORE NEWS
![Infosys Withdraws...](https://im.rediff.com/80-80/money/2021/sep/01gst.jpg)
Infosys Withdraws GST Notice: Rs 32,403 Crore...
Infosys has received a communication from Karnataka authorities withdrawing the GST...
![Airbnb, IAFCI...](https://im.rediff.com/80-80/money/2016/aug/10airbnb.jpg)
Airbnb, IAFCI Partner to Fight Travel Scams | News
Airbnb and IAFCI team up to protect consumers from travel scams. Learn how to avoid...
![Ola Electric IPO:...](https://im.rediff.com/80-80/money/2023/jan/19ola-electric.jpg)
Ola Electric IPO: Rs 2,763 cr Raised from...
Ola Electric Mobility has raised Rs 2,763 crore from anchor investors ahead of its IPO,...